Functional Healthcare
- Ozone Therapy
- IV Therapy
- Hyperbaric Oxygen Therapy (HBOT)
- Lyme Disease Treatment
- Peptide Therapy
Omaha, NE
Omaha's IV therapy market is steady and well-established for a Midwest metro, supported by a strong corporate presence (Berkshire Hathaway, Mutual of Omaha, Union Pacific) and a medical-heavy employer base anchored by Nebraska Medicine and CHI Health. Clinics cluster in Midtown, Dundee, Aksarben, and along Dodge Street west through Regency and 180th, with growth in Elkhorn. Nebraska Medicine, Methodist Health System, and CHI Health supply many medical directors. Nebraska is a full-practice state for nurse practitioners, so NP-led IV clinics are common alongside physician-director models. Cold winters drive immune drip demand from November through March, the College World Series in June brings mobile IV activity around downtown hotels, and the city's runner scene (Omaha Marathon) supports athletic recovery bookings. Corporate executive wellness and B12 protocols are a steady category.
Regulatory context
FDA regulates the compounded ingredients used in IV therapy and the facilities that prepare them. Patient-specific compounded IVs fall under FDCA Section 503A, while bulk preparations for office use fall under Section 503B (outsourcing facilities). USP Chapter 797 governs sterile compounding standards. FDA has issued warnings about injectable glutathione marketed for skin lightening (2017) and has not approved NAD IV for any specific indication. Vitamin and mineral IV mixtures such as the Myers cocktail are compounded preparations and are not FDA-approved drug products.
The Nebraska medical and nursing boards have addressed unlicensed practice in medical spa and IV lounge settings. Common enforcement themes include IV therapy administered without a valid physician order, stale or missing standing orders, absence of a designated medical director, and unlicensed personnel performing venipuncture. Boards have reiterated that a prescribing physician or APRN must establish a bona fide patient relationship before any IV protocol is initiated, and that standing orders must be specific, dated, and periodically reviewed.